Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

53.57 +1.66 (+3.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday
Although the company recorded higher sales overall, it's decided to divest one of its products. 
Via The Motley Fool
Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 4.5% in the morning session after the company reported third-quarter earnings, which featured a significant earnings miss but a... 
Via StockStory
Topics Earnings Economy Government
Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings
 
Via Benzinga
BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was... 
Via StockStory
BioMarin (BMRN) Q3 2025 Earnings Call Transcript
BioMarin (BMRN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Mixed Q3 2025 Results with Revenue Growth but Earnings Miss
BioMarin's Q3 2025 results show mixed performance with revenue growth but a significant earnings miss, while the company raises its full-year outlook. 
Via Chartmill
Topics Earnings
BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was... 
Via StockStory
BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results this Monday after market close. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Earnings Scheduled For October 27, 2025
 
Via Benzinga
What to Expect from Biomarin Pharmaceutical's Earnings
 
Via Benzinga
3 of Wall Street’s Favorite Stocks to Target This Week
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
1 Healthcare Stock Worth Investigating and 2 We Question
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
1 Mid-Cap Stock to Research Further and 2 That Underwhelm
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
Is BioMarin Pharmaceutical Inc Gaining or Losing Market Support?
 
Via Benzinga
6 Analysts Assess BioMarin Pharmaceutical: What You Need To Know
 
Via Benzinga
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case
BioMarin is a strong value stock with a low P/E ratio, robust financial health, and solid profitability, offering a compelling safety margin for investors. 
Via Chartmill
Peering Into BioMarin Pharmaceutical's Recent Short Interest
 
Via Benzinga
2 Profitable Stocks on Our Watchlist and 1 We Turn Down
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
Via Benzinga
Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) fell 2.8% in the morning session after HC Wainwright & Co. initiated coverage on the stock with a Neutral rating and a $60 price target. 
Via StockStory
Topics Artificial Intelligence Economy
Forecasting The Future: 5 Analyst Projections For BioMarin Pharmaceutical
 
Via Benzinga
This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
2 Growth Stocks to Stash and 1 We Ignore
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Investing Case Study in Undervaluation
BioMarin Pharmaceutical (BMRN) is a top value investing pick, trading at a discount with strong financial health, high profitability, and solid growth potential. 
Via Chartmill
2 Safe-and-Steady Stocks to Keep an Eye On and 1 Facing Challenges
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
What's Driving the Market Sentiment Around BioMarin Pharmaceutical?
 
Via Benzinga
3 of Wall Street’s Favorite Stocks to Consider Right Now
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
2 Reasons to Watch BMRN and 1 to Stay Cautious
Over the past six months, BioMarin Pharmaceutical’s stock price fell to $57. Shareholders have lost 17.1% of their capital, which is disappointing considering the S&P 500 has climbed by 4.7%. This may... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.